Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention

Drug Profile

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention

Alternative Names: Ad26 Mos HIV; Ad26 Mos HIV + clade C gp140; Ad26 mosaic vector + gp140; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos.HIV + gp140; Adenovirus-serotype-26-Mosaic-HIV-vaccine; Adenovirus-serotype-26-Mosaic-HIV-vaccine + Clade C glycoprotein 140

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative; Janssen Vaccines and Prevention B.V; U.S. Military HIV Research Program
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 24 Jul 2018 Updated adverse events and immunogenicity data from the phase I/II APPROACH trial in HIV infections presented at the 22nd International AIDS Conference (IAC-2018)
  • 13 Jul 2018 Updated immunogenicity data from the phase I/IIa APPROACH trial and pharmacodynamics data from a parallel bridging study in HIV infections released by Janssen Vaccines and Prevention
  • 08 Mar 2018 Crucell Holland completes a phase I trial for HIV infections (Prevention) in USA (IM) (NCT02685020)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top